Press Releases Filter Options Archive DateYear20262025202420232022202120202019201820172016201520142013201220112010200920082007MonthJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember View 12 View 12View 24View 48 Categories CorporateFinancialPrescription MedicinesResearch and PipelineSocial ResponsibilityVaccines Keywords All Keywords Covid-19FinanceInvestmentsLeadershipMedicinesPartnershipsResearchResponsibilityVaccines October 2023 10.13.2023 Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 GuidanceCorporateFinance May 2023 05.25.2023 Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19Prescription Medicines March 2023 03.16.2023 FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™Covid-19Medicines September 2022 09.22.2022 Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income CountriesPrescription MedicinesMedicines June 2022 06.30.2022 Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™Prescription MedicinesMedicines 06.14.2022 Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDAPrescription MedicinesMedicines
